Coloplast's faith in a potential vapor ablation treatment for prostate cancer has grown stronger, having participated in a series B equity financing round of the US-based medtech company behind the treatment, the Danish company reports in its year-end report from 2020/2021.
Francis Medical has previously announced that the Series B financing round has brought the company USD 55m in funding. The Series B round was led by venture capital firm Solas Bioventures with previous investors participating, including Coloplast, which became an investor in the company with USD 4m in September 2020.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.